The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

M&A boost on euro bond market horizon

Fri, 08th Aug 2014 08:36

* Euro corporate bond market gears up for bumper H2

* More hybrid deals expected

* M&A borrowers face leverage risks

By Laura Benitez

August 8 (IFR) - The European corporate bond market isexpected to reload early after the summer break and is gearingup for a bumper second half of the year as issuers keen torefinance M&A bridge loans prepare to tap the market.

Debt capital markets bankers have been hoping for some timefor a pick-up in M&A activity to bolster primary bond marketvolumes and it looks as if their hopes are finally coming truein 2014.

According to Thomson Reuters data, year-to-date global M&Aactivity totals US$2.2trn, up 66% from the same period lastyear, while July's total of US$428.5bn is the highest monthlylevel since 2007.

"We're going to see more activity in the European investmentbond market coming from the increase in M&A financing; it'sdefinitely shaping up to be a busy September," said a syndicatebanker, who added that the market had plenty of capacity toabsorb extra supply.

A head of syndicate echoed this view, adding that he wasworking on eight upcoming M&A-related bond issues. There iscurrently 63.2bn worth of European bridge loans due to maturebefore the end of 2015, while European leveraged syndicatedvolume year to date stands at 85.5bn, according to ThomsonReuters data.

Increased M&A activity partly stems from the wave ofso-called tax inversion driven deals that have flooded the M&Amarket over recent months. Companies have been eagerlyapproaching targets ahead of new US tax rules that are expectedto come into play on January 1 2015.

The rules will restrict companies from inverting: a methodwhere businesses are restructured abroad to adopt new taxjurisdictions for 20% of the combined entity's stock.

"It makes sense for those US companies that have globaloperations and a mid-level investment grade and Europeanprofile, and those with chunky funding size requirements totarget European investors. Some of these deals will be as largeas US$20bn, while others are much smaller at US$5bn," the headof syndicate said.

The European corporate bond market has so far coped wellwith an increase in supply and volumes year to date are ahead oflast year's, at more than 169.8bn-equivalent compared to the140.1bn according to Thomson Reuters data.

BIGGER, BOLDER

Corporates are expected to use every available tool in thetreasurer's tool box, with hybrids making up an important partof the financing mix, according to market participants.

Already, the volume of hybrid bonds issued so far this yeartotals more than 27bn-equivalent, compared to 25.4bn-equivalent in the same period last year, according to ThomsonReuters data.

One syndicate banker said the corporate bond market isundergoing a change in dynamic, in which subordinated and hybriddeals are becoming a standardised product with moreintraday-executed transactions being seen.

"It's changed the landscape for hybrid deals. We'll beseeing low-beta names issuing these deals in the near future,and they will attract investors chasing bigger yields and moreflexible tenors and ratings," he said.

Meanwhile, dual-tranche deals, especially from the biggernames that have been spurred on by increased risk appetite, arealso expected.

LEVERAGING UP

However, while the market appears to be firing on allcylinders, the increase in M&A is not without risks.

"While the overall leverage ratios remain in check, the sizeof deals and consequent aggregate borrowing has been increasing,and this is a trend that we expect to see continue," saidanalysts at Henderson.

"Borrowers are also being more innovative in how they usedebt to fund deals, with the use of term loans to pre-financesmaller deals entirely rather than requiring costly bridgeloans, while on larger deals we see far more use of bond dealswith tranches across multiple currencies."

In a note published at the end of July, S&P warned thatwhile acquisitions in this cycle had been generally supportivefor credit quality, rising leverage levels could change thisfeature of the M&A rebound in Europe.

Meanwhile, a number of corporates have either already beendowngraded or put on negative outlook. Fitch downgraded Vodafoneto BBB+ from A- in early August, citing the increase in leverageresulting from the acquisition of 100% of the share capital ofONO.

GlaxoSmithKline is another example of a corporate being hitby a downgrade because of M&A. The issuer's A1 Moody's ratingwas moved to A2 in early August, partly because of the "materialcontingent liability arising from a put option granted toNovartis as part of a three-leg M&A transaction signed earlierthis year," the agency said in a statement.

British Sky Broadcasting Group's BBB+ Fitch rating could becut by two notches if its acquisition of 100% of Sky Italia and a 57.4% stake in Sky Deutschland from 21st Century Fox goesahead. (Reporting By Laura Benitez, Editing by Helene Durand andPhilip Wright)

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.